These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29848571)

  • 1. Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.
    Bhatia S; Sharma J; Bukkapatnam S; Oweida A; Lennon S; Phan A; Milner D; Uyanga N; Jimeno A; Raben D; Somerset H; Heasley L; Karam SD
    Clin Cancer Res; 2018 Sep; 24(18):4539-4550. PubMed ID: 29848571
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers.
    Bhatia S; Oweida A; Lennon S; Darragh LB; Milner D; Phan AV; Mueller AC; Van Court B; Raben D; Serkova NJ; Wang XJ; Jimeno A; Clambey ET; Pasquale EB; Karam SD
    Cancer Res; 2019 May; 79(10):2722-2735. PubMed ID: 30894369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
    Masood R; Kumar SR; Sinha UK; Crowe DL; Krasnoperov V; Reddy RK; Zozulya S; Singh J; Xia G; Broek D; Schönthal AH; Gill PS
    Int J Cancer; 2006 Sep; 119(6):1236-48. PubMed ID: 16615113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.
    Bhatia S; Hirsch K; Sharma J; Oweida A; Griego A; Keysar S; Jimeno A; Raben D; Krasnoperov V; Gill PS; Pasquale EB; Wang XJ; Karam SD
    Sci Rep; 2016 Dec; 6():38792. PubMed ID: 27941840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
    Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination.
    Lennon S; Oweida A; Milner D; Phan AV; Bhatia S; Van Court B; Darragh L; Mueller AC; Raben D; Martínez-Torrecuadrada JL; Pitts TM; Somerset H; Jordan KR; Hansen KC; Williams J; Messersmith WA; Schulick RD; Owens P; Goodman KA; Karam SD
    Clin Cancer Res; 2019 Jun; 25(11):3352-3365. PubMed ID: 30944125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment.
    Bhatia S; Nguyen D; Darragh LB; Van Court B; Sharma J; Knitz MW; Piper M; Bukkapatnam S; Gadwa J; Bickett TE; Bhuvane S; Corbo S; Wu B; Lee Y; Fujita M; Joshi M; Heasley LE; Ferris RL; Rodriguez O; Albanese C; Kapoor M; Pasquale EB; Karam SD
    Nat Commun; 2022 Jun; 13(1):3535. PubMed ID: 35725568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EphB and Ephrin-B interactions mediate human mesenchymal stem cell suppression of activated T-cells.
    Nguyen TM; Arthur A; Hayball JD; Gronthos S
    Stem Cells Dev; 2013 Oct; 22(20):2751-64. PubMed ID: 23711177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ephrin B2/EphB4 mediates the actions of IGF-I signaling in regulating endochondral bone formation.
    Wang Y; Menendez A; Fong C; ElAlieh HZ; Chang W; Bikle DD
    J Bone Miner Res; 2014 Aug; 29(8):1900-13. PubMed ID: 24677183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
    Piffko A; Broggini T; Harms C; Adams RH; Vajkoczy P; Czabanka M
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
    Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.
    Baro M; Lopez Sambrooks C; Burtness BA; Lemmon MA; Contessa JN
    Mol Cancer Ther; 2019 Nov; 18(11):2124-2134. PubMed ID: 31387891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
    Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
    Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
    Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
    Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors.
    Oweida A; Bhatia S; Hirsch K; Calame D; Griego A; Keysar S; Pitts T; Sharma J; Eckhardt G; Jimeno A; Wang XJ; Parkash G; Califano J; Karam SD
    Mol Carcinog; 2017 Mar; 56(3):1189-1196. PubMed ID: 27649287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
    Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
    J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A narrative review of the role of Eph receptors in head and neck squamous cell carcinoma.
    Al-Jamaei AAH; Subramanyam RV; Helder MN; Forouzanfar T; van der Meij EH; Al-Jamei S; de Visscher JGAM
    Oral Dis; 2024 Apr; 30(3):833-845. PubMed ID: 37279081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
    Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
    Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.